Outlook Therapeutics, Inc. (OTLK)
| Market Cap | 221.18M +170.2% |
| Revenue (ttm) | 333,141 |
| Net Income | -60.96M |
| EPS | -1.08 |
| Shares Out | 120.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,789,459 |
| Open | 1.580 |
| Previous Close | 1.580 |
| Day's Range | 1.470 - 1.880 |
| 52-Week Range | 0.161 - 3.390 |
| Beta | 0.98 |
| Analysts | Buy |
| Price Target | 5.50 (+200.55%) |
| Earnings Date | May 15, 2026 |
About OTLK
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for OTLK stock is "Buy." The 12-month stock price target is $5.5, which is an increase of 200.55% from the latest price.
News
Outlook Therapeutics resubmits ONS-5010 biologics license application to FDA
Outlook Therapeutics (OTLK) announced the FDA has acknowledged receipt of the resubmission of the biologics license application, or BLA, for ONS-5010/Lytenava for the treatment of neovascular age-rela...
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
ISELIN, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re...
Outlook Therapeutics resubmits biologics license application to FDA
Outlook Therapeutics (OTLK) announced the resubmission of its biologics license application, or BLA, to the FDA for ONS-5010/Lytenava for the treatment of neovascular age-related macular degeneration.
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizum...
Outlook Therapeutics Proxy statement: Proxy filing
Outlook Therapeutics filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Outlook Therapeutics Proxy statement: Proxy filing
Outlook Therapeutics filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Outlook Therapeutics announces pricing of $5M registered direct offering
Outlook Therapeutics (OTLK) announced that it has entered into a definitive agreement providing for the purchase and sale of an aggregate of 8.54M shares of its common stock at a…
Outlook to sell 8.54M shares at 58.55c in registered direct offering
Outlook Therapeutics (OTLK) announced that it has entered into a definitive agreement providing for the purchase and sale of an aggregate of 8.54M shares of its common stock at a…
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
ISELIN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizuma...
Outlook Therapeutics wins appeal following FDR process for ONS-5010/Lytenava
Outlook Therapeutics (OTLK) announced that the U.S. Food and Drug Administration, FDA, has granted the appeal following completion of the Formal Dispute Resolution, FDR, process with the Office of New...
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
ISELIN, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizuma...
Outlook Therapeutics Proxy statement: Proxy filing
Outlook Therapeutics filed a proxy statement on May 22, 2026, providing details for shareholder voting and corporate governance matters.
Outlook Therapeutics downgraded to Neutral from Buy at BTIG
BTIG downgraded Outlook Therapeutics (OTLK) to Neutral from Buy with no price target While the firm believes Lytenava has inherent benefits over compounded bevacizumab in wet age-related macular degen...
Outlook Therapeutics reports Q2 adjusted EPS (16c), consensus (12c)
Reports Q2 revenue $128,000, consensus $4.4M. “We remain committed to working collaboratively with the FDA to establish a clear path forward toward potential U.S. approval. Our objective is clear: to…
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
ISELIN, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ret...
Outlook Therapeutics Quarterly report: Q2 2026
Outlook Therapeutics has published its Q2 2026 quarterly earnings report on May 15, 2026.
Outlook Therapeutics Earnings release: Q2 2026
Outlook Therapeutics released its Q2 2026 earnings on May 15, 2026, summarizing the period's financial results.
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of c...
Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering
Outlook Therapeutics (OTLK) announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16.129M shares of its common stock at an offering…
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of c...
Outlook Therapeutics completes Federal Dispute Resolution meeting with FDA
Outlook Therapeutics (OTLK) announced that it has completed its Federal Dispute Resolution meeting with the Office of New Drugs at the U.S. Food and Drug Administration. The meeting was conducted…
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
ISELIN, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r...
Outlook Therapeutics submits formal dispute resolution request to FDA
Outlook Therapeutics (OTLK) announced that it submitted a formal dispute resolution request to the FDA as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete…
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r...
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r...